Across TCGA pan-cancer cohorts, MIR3684 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of MIR3684’s most consistent transcriptional readouts.
The strongest signal is observed in breast invasive carcinoma (BRCA), where MIR3684 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MIR3684 is over-expressed in tumor.
BRCA and LUSC are the cancer types where MIR3684 tumor–normal differential expression is most reproducible.